TACSTD2 and ovarian cancer: In 2023, the M.D. Anderson Cancer Center initiated two clinical studies (NCT05922930 and NCT06066424) to evaluate Trop2 CAR-engineered IL15-transduced cord blood-derived NK cells in patients with platinum-resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer.